[{"from": "human", "value": "Describe this molecule. [C][C@H1][Branch2][Ring1][Ring2][C][C][C@H1][Branch1][=Branch1][C][Branch1][C][C][C][O][S][=Branch1][C][=O][=Branch1][C][=O][O][C@H1][C][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring2][O][C][C][C@H1][C@H1][Ring1][=Branch1][C@@H1][Branch2][Ring1][S][C][C@@H1][C@@][Ring1][=Branch1][Branch2][Ring1][#Branch1][C][C][C@@H1][Branch1][Ring2][C][Ring1][=Branch1][N][C][C][C][N][C][C][C][C][N][C][C][C][N][C][O][C]"}, {"from": "gpt", "value": "The molecule is a naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance."}]